Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTNNB1 | P35222 | 7/20 | 0.54 |
| ▸ | WNT3A | P56704 | 7/20 | 0.54 |
| ▸ | HTR1B | P28222 | 1/20 | 0.54 |
| ▸ | IDO1 | P14902 | 9/20 | 0.51 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.46 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.44 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28431104 | 0.84 | CTNNB1 (0.59) | CTNNB1WNT3AHTR1BIDO1CYP2A6 | |
| SCHEMBL103953 | 0.84 | CTNNB1 (0.59) | CTNNB1WNT3AHTR1BIDO1CYP2A6 | |
| SCHEMBL663873 | 0.78 | CTNNB1 (0.63) | CTNNB1WNT3AHTR1BIDO1CYP2A6 | |
| SCHEMBL4318315 | 0.78 | CTNNB1 (0.58) | CTNNB1WNT3AHTR1BIDO1CYP2A6 | |
| SCHEMBL29987426 | 0.78 | CTNNB1 (0.63) | CTNNB1WNT3AHTR1BIDO1CYP2A6 | |
| SCHEMBL1019302 | 0.76 | CTNNB1 (0.57) | CTNNB1WNT3AHTR1BIDO1CYP2A6 | |
| SCHEMBL563348 | 0.76 | F2 (0.53) | CTNNB1WNT3AHTR1BIDO1 | |
| SCHEMBL3441414 | 0.76 | AR (0.61) | CTNNB1WNT3AHTR1BIDO1CYP2A6 | |
| SCHEMBL25285106 | 0.76 | CTNNB1 (0.55) | CTNNB1WNT3AHTR1BIDO1CYP2A6 | |
| SCHEMBL12020481 | 0.76 | HTR1B (0.63) | CTNNB1WNT3AHTR1BTAS1R3TAS1R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180327401-A1 | IMIDAZOLIN-5-ONE DERIVATIVE USEFUL AS FASN INHIBITORS FOR THE TREATMENT OF CANCER | JANSSEN PHARMACEUTICA NV (BE) | 2018-11-15 | — | — | US | disclosed |
| US-10077261-B2 | Imidazolin-5-one derivative useful as FASN inhibitors for the treatment of cancer | JANSSEN PHARMACEUTICA NV (BE) | 2018-09-18 | — | — | US | disclosed |
| US-20160002219-A1 | IMIDAZOLIN-5-ONE DERIVATIVE USEFUL AS FASN INHIBITORS FOR THE TREATMENT OF CANCER | JANSSEN PHARMACEUTICA NV (BE) | 2016-01-07 | — | — | US | disclosed |
| US-20150099730-A1 | IMIDAZOLIN-5-ONE DERIVATIVE USEFUL AS FASN INHIBITORS FOR THE TREATMENT OF CANCER | JANSSEN PHARMACEUTICA, NV (BE) | 2015-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150099730-A1 | IMIDAZOLIN-5-ONE DERIVATIVE USEFUL AS FASN INHIBITORS FOR THE TREATMENT OF CANCER | FASN, PLIN1, FABP1 | CTNNB1 4568/4885WNT3A 3805/4885HTR1B 1860/4885 |
| US-10077261-B2 | Imidazolin-5-one derivative useful as FASN inhibitors for the treatment of cancer | FASN, PLIN1, FABP1 | CTNNB1 4568/4885WNT3A 3805/4885HTR1B 1860/4885 |
| US-20180327401-A1 | IMIDAZOLIN-5-ONE DERIVATIVE USEFUL AS FASN INHIBITORS FOR THE TREATMENT OF CANCER | FASN, PLIN1, FABP1 | CTNNB1 4568/4885WNT3A 3805/4885HTR1B 1860/4885 |
| US-20160002219-A1 | IMIDAZOLIN-5-ONE DERIVATIVE USEFUL AS FASN INHIBITORS FOR THE TREATMENT OF CANCER | FASN, PLIN1, FABP1 | CTNNB1 4568/4885WNT3A 3805/4885HTR1B 1860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.